Acylated and unacylated ghrelin administration to blunt muscle wasting
Current Opinion in Clinical Nutrition & Metabolic Care: May 2014 - Volume 17 - Issue 3 - p 236-240 Reano, Simone
Muscle wasting is a comorbidity often associated with a wide range of disorders that severely affects patient prognosis and quality of life. Ghrelin, through its receptor GHSR-1a, stimulates appetite and growth hormone (GH) release. Several studies indicate that ghrelin administration is a valid treatment for cachexia because it improves muscle mass and function, likely by restoring a positive energy balance.
In addition to its GHSR-1a-mediated effects on muscle mass, ghrelin acts directly on skeletal muscle, wherein it exerts a protective activity against muscle wasting. This direct activity is independent of GHSR-1a and is shared by the unacylated form of ghrelin, which does not bind GHSR-1a and is devoid of the effects on appetite and GH release.
Both the acylated and unacylated forms of ghrelin might have therapeutic potential for the treatment of skeletal muscle wasting.
Voir aussi :
- Urolithine B comme un nouveau régulateur de la masse musculaire
- Comment la santé des reins affecte la masse musculaire?
- L'ibuprofène contre la fatigue?
- La brûlure musculaire est neuroprotectrice
- Efficacité des injections de prolothérapie contre les tendinites?